Targeting Histone H3K36me3-deficient CancersWednesday, 27 January 2016 at 15:30 Add to Calendar ▼2016-01-27 15:30:002016-01-27 16:30:00Europe/LondonTargeting Histone H3K36me3-deficient CancersEpigenetics in Drug Discovery in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com Loss of the histone H3K36me3 mark is frequently observed in cancer cells, suggesting this epigenetic mark as an important therapeutic target. Evidence will be presented indicating that H3K36me3-deficient cancer cells can be effectively targeted using the WEE1 inhibitor AZD1775. The underlying mechanism of this synthetic lethality and its implications will be discussed. |